Literature DB >> 29687324

Imaging VEGF Receptors and αvβ3 Integrins in a Mouse Hindlimb Ischemia Model of Peripheral Arterial Disease.

Yared Tekabe1, Qing Li2, Geping Zhang2, Jordan Johnson2, Ann Marie Schmidt3, Marina Backer4, Joseph Backer4, Lynne L Johnson2.   

Abstract

PURPOSE: To compare targeted imaging of vascular endothelial growth factor (VEGF) receptors vs. αvβ3 integrins in a mouse hindlimb ischemia model of peripheral artery disease. PROCEDURES: Male wild-type (WT) C57BL/6 mice (8- to 10-week old) (n = 24) underwent left femoral artery ligation. The right leg served as control. Five days later, mice were injected with either VEGF receptor targeting [99mTc]DOTA-PEG-scVEGF ([99mTc]scV) (n = 8) or with αvβ3-targeting tracer [99mTc]HYNIC-cycloRGD ([99mTc]RGD) (n = 8) and underwent single photon emission computed tomography (SPECT) x-ray computed tomography imaging. To assess non-specific [99mTc]scV uptake, six additional mice received a mixture of [99mTc]scV and 30-fold excess of targeting protein, scVEGF. Tracer uptake as %ID was measured using volumetric regions encompassing the hindlimb muscles and as %ID/g from harvested limb muscles. Double and triple immunofluorescent analysis on tissue sections established localization of αvβ3, VEGFR-1, VEGFR-2, as well as certain cell lineage markers.
RESULTS: Tracer uptake, as %ID/g, was higher in ligated limbs of mice injected with [99mTc]scV compared to ligated hindlimbs in mice injected with [99mTc]RGD (p = 0.02). The ratio of tracer uptake for ligated/control hindlimb was borderline higher for [99mTc]scV than for [99mTc]RGD (p = 0.06). Immunofluorescent analysis showed higher prevalence of VEGFR-1, VEGFR-2, and αvβ3, in damaged vs. undamaged hindlimb tissue, but with little co-localization of these markers. Double immunofluorescent staining showed partial co-localization of VEGFR-1, VEGFR-2, and αvβ3, with endothelial cell marker FVIII, but not with CD31. Immunostaining for VEGFR-1 and VEGFR-2 additionally co-localized with lineage markers for endothelial progenitor cell and monocytes/macrophages, with a more diverse pattern of co-localization for VEGFR-2.
CONCLUSION: In a mouse hindlimb ischemia model of peripheral artery disease, [99mTc]scV SPECT tracer-targeting VEGF receptors showed a more robust signal than [99mTc]RGD tracer-targeting αvβ3. Immunofluorescent analysis suggests that uptake of [99mTc]scV and [99mTc]RGD in damaged tissue is due to non-overlapping cell populations and reflects different dynamic processes and that enhanced uptake of [99mTc]scV may be due to the presence of VEGF receptors on additional cell types.

Entities:  

Keywords:  Angiogenesis; Hindlimb ischemia; RGD; Vascular endothelial growth factor

Mesh:

Substances:

Year:  2018        PMID: 29687324     DOI: 10.1007/s11307-018-1191-1

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  54 in total

1.  Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II).

Authors:  L Norgren; W R Hiatt; J A Dormandy; M R Nehler; K A Harris; F G R Fowkes
Journal:  J Vasc Surg       Date:  2007-01       Impact factor: 4.268

Review 2.  Integrins: signaling, disease, and therapy.

Authors:  Stephan Huveneers; Hoa Truong; H J Danen
Journal:  Int J Radiat Biol       Date:  2007 Nov-Dec       Impact factor: 2.694

3.  Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors.

Authors:  M Peichev; A J Naiyer; D Pereira; Z Zhu; W J Lane; M Williams; M C Oz; D J Hicklin; L Witte; M A Moore; S Rafii
Journal:  Blood       Date:  2000-02-01       Impact factor: 22.113

4.  VEGF165b Modulates Endothelial VEGFR1-STAT3 Signaling Pathway and Angiogenesis in Human and Experimental Peripheral Arterial Disease.

Authors:  Vijay Chaitanya Ganta; Min Choi; Anna Kutateladze; Brian H Annex
Journal:  Circ Res       Date:  2016-12-14       Impact factor: 17.367

5.  Plasminogen activator inhibitor-1 inhibits angiogenic signaling by uncoupling vascular endothelial growth factor receptor-2-αVβ3 integrin cross talk.

Authors:  Jianbo Wu; Tammy L Strawn; Mao Luo; Liqun Wang; Rong Li; Meiping Ren; Jiyi Xia; Zhuo Zhang; Weizhong Ma; Tingting Luo; Daniel A Lawrence; William P Fay
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-11-06       Impact factor: 8.311

6.  [99mTc]HYNIC-RGD for imaging integrin alphavbeta3 expression.

Authors:  Clemens Decristoforo; Bluma Faintuch-Linkowski; Ana Rey; Elisabeth von Guggenberg; Marco Rupprich; Ignacio Hernandez-Gonzales; Teodoro Rodrigo; Roland Haubner
Journal:  Nucl Med Biol       Date:  2006-11       Impact factor: 2.408

7.  Direct site-specific labeling of the Cys-tag moiety in scVEGF with technetium 99m.

Authors:  Zoia Levashova; Marina Backer; Joseph M Backer; Francis G Blankenberg
Journal:  Bioconjug Chem       Date:  2008-04-12       Impact factor: 4.774

8.  Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin.

Authors:  D R Senger; S R Ledbetter; K P Claffey; A Papadopoulos-Sergiou; C A Peruzzi; M Detmar
Journal:  Am J Pathol       Date:  1996-07       Impact factor: 4.307

9.  Macrophage Recruitment and Polarization During Collateral Vessel Remodeling in Murine Adipose Tissue.

Authors:  Scott A Seaman; Yiqi Cao; Chris A Campbell; Shayn M Peirce
Journal:  Microcirculation       Date:  2016-01       Impact factor: 2.628

Review 10.  Arginine-Glycine-Aspartate-Binding Integrins as Therapeutic and Diagnostic Targets.

Authors:  Cui-Cui Sun; Xian-Jun Qu; Zu-Hua Gao
Journal:  Am J Ther       Date:  2016 Jan-Feb       Impact factor: 2.688

View more
  1 in total

1.  VEGF receptor targeted imaging of angiogenic response to limb ischemia in diabetic vs. non-diabetic Yucatan minipigs.

Authors:  Lynne L Johnson; Jordan Johnson; Ziad Ali; Yared Tekabe; Rebecca Ober; Gail Geist; Alicia McLuckie; Aram Safarov; April Holland; Geping Zhang; Marina Backer; Joseph Backer
Journal:  EJNMMI Res       Date:  2020-05-12       Impact factor: 3.138

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.